234 related articles for article (PubMed ID: 36034827)
1. Oxaliplatin Eluting CalliSpheres Microspheres for the Treatment of Unresectable or Recurrent Hepatocellular Carcinoma.
Bi Y; Ren K; Ren J; Ma J; Han X
Front Pharmacol; 2022; 13():923585. PubMed ID: 36034827
[No Abstract] [Full Text] [Related]
2. Clinical outcomes of doxorubicin-eluting CalliSpheres® beads-transarterial chemoembolization for unresectable or recurrent esophageal carcinoma.
Bi Y; Shi X; Ren J; Yi M; Han X; Song M
BMC Gastroenterol; 2021 May; 21(1):231. PubMed ID: 34020608
[TBL] [Abstract][Full Text] [Related]
3. The safety and efficacy of oxaliplatin-loaded drug-eluting beads transarterial chemoembolization for the treatment of unresectable or advanced lung cancer.
Bi Y; Li F; Ren J; Han X
Front Pharmacol; 2022; 13():1079707. PubMed ID: 36518678
[No Abstract] [Full Text] [Related]
4. Efficacy and safety of raltitrexed-eluting CalliSpheres
Sun Z; Jiao D; Fang Y; Liu Y; Xu K; Zhang C; Huang Y; Han X
Ther Adv Med Oncol; 2024; 16():17588359241229661. PubMed ID: 38362379
[TBL] [Abstract][Full Text] [Related]
5. Clinical Outcomes of Drug-Eluting Bead Transarterial Chemoembolization Loaded with Raltitrexed for the Treatment of Unresectable or Recurrent Hepatocellular Carcinoma.
Bi Y; Jiao D; Ren J; Han X
Can J Gastroenterol Hepatol; 2022; 2022():2602121. PubMed ID: 36051250
[TBL] [Abstract][Full Text] [Related]
6. Preliminary outcomes of DEB-TACE loaded with raltitrexed in the treatment of unresectable or recurrent hepatocellular carcinoma.
Bi Y; Wang Y; Zhang W; Lu H; Ren J; Han X
Cancer Imaging; 2023 Feb; 23(1):19. PubMed ID: 36814327
[TBL] [Abstract][Full Text] [Related]
7. Transarterial chemoembolization of unresectable renal cell carcinoma with doxorubicin-loaded CalliSpheres drug-eluting beads.
Bi Y; Shi X; Ren J; Yi M; Han X
Sci Rep; 2022 May; 12(1):8136. PubMed ID: 35581365
[TBL] [Abstract][Full Text] [Related]
8. Clinical outcomes of gemcitabine-loaded callispheres drug-eluting beads for patients with advanced and inoperable lung cancer: A case series study.
Bi Y; Zhang B; Ren J; Han X; Wu W
Front Pharmacol; 2022; 13():992526. PubMed ID: 36249775
[No Abstract] [Full Text] [Related]
9. Comparison of CalliSpheres
Shi Z; Wang D; Kang T; Yi R; Cui L; Jiang H
Radiol Oncol; 2023 Mar; 57(1):70-79. PubMed ID: 36794998
[TBL] [Abstract][Full Text] [Related]
10. Preliminary outcomes of raltitrexed eluting bead-transarterial chemoembolization using Callispheres® beads for gastrointestinal adenocarcinoma liver metastasis.
Bi Y; Jiao D; Wang Y; Han X; Ren J
World J Surg Oncol; 2022 Jul; 20(1):229. PubMed ID: 35821043
[TBL] [Abstract][Full Text] [Related]
11. Efficacy, safety, and prognostic factors of drug-eluting beads transarterial chemoembolization using CalliSpheres in treating huge hepatocellular carcinoma patients.
Wang Z; Mu K; Lv Y; Zhao L; Li B; Hao Y; Wang N
Ir J Med Sci; 2022 Dec; 191(6):2493-2499. PubMed ID: 35064533
[TBL] [Abstract][Full Text] [Related]
12. Comparison of DEB-TACE and cTACE for the initial treatment of unresectable hepatocellular carcinoma beyond up-to-seven criteria: A single-center propensity score matching analysis.
Shi Q; Liu J; Li T; Zhou C; Wang Y; Huang S; Yang C; Chen Y; Xiong B
Clin Res Hepatol Gastroenterol; 2022 May; 46(5):101893. PubMed ID: 35247625
[TBL] [Abstract][Full Text] [Related]
13. CalliSpheres drug-eluting beads versus lipiodol transarterial chemoembolization in the treatment of hepatocellular carcinoma: a short-term efficacy and safety study.
Wu B; Zhou J; Ling G; Zhu D; Long Q
World J Surg Oncol; 2018 Mar; 16(1):69. PubMed ID: 29587773
[TBL] [Abstract][Full Text] [Related]
14. The second-line treatment of hepatocellular carcinoma with CalliSpheres drug-eluting bead transarterial chemoembolization combined with regorafenib: A safety and efficacy analysis.
Liu S; Liu C; Wang Q; Liu Y; Wang D; Zhao G; Yu G
Ir J Med Sci; 2024 Jun; 193(3):1215-1222. PubMed ID: 38300460
[TBL] [Abstract][Full Text] [Related]
15. Short-term efficacy and safety of callispheres drug-loaded microsphere embolization in primary hepatocellular carcinoma.
Li J; Wang N; Shi C; Liu Q; Song J; Ye X
J Cancer Res Ther; 2021 Jul; 17(3):733-739. PubMed ID: 34269307
[TBL] [Abstract][Full Text] [Related]
16. Callispheres® drug-eluting beads transarterial chemoembolization might be an efficient and safety down-staging therapy in unresectable liver cancer patients.
Peng N; Mao L; Tao Y; Xiao K; Yuan G; He S
World J Surg Oncol; 2022 Aug; 20(1):254. PubMed ID: 35941634
[TBL] [Abstract][Full Text] [Related]
17. A comparative study of efficacy and safety of transarterial chemoembolization with CalliSpheres and conventional transarterial chemoembolization in treating unresectable intrahepatic cholangiocarcinoma patients.
Sun T; Zhang W; Chen L; Ren Y; Liu Y; Zheng C
J Cancer; 2022; 13(4):1282-1288. PubMed ID: 35281867
[No Abstract] [Full Text] [Related]
18. Drug-eluting bead transarterial chemoembolization with medium-sized versus small-sized CalliSpheres microspheres in unresectable primary liver cancer.
Zhang J; Feng GA; Li Y; Wang W
Asia Pac J Clin Oncol; 2022 Aug; 18(4):388-393. PubMed ID: 34708554
[TBL] [Abstract][Full Text] [Related]
19. Pirarubicin-loaded CalliSpheres® drug-eluting beads for the treatment of patients with stage III-IV lung cancer.
Bi Y; Shi X; Yi M; Han X; Ren J
Acta Radiol; 2022 Mar; 63(3):311-318. PubMed ID: 33615822
[TBL] [Abstract][Full Text] [Related]
20. Lipiodol combined with drug-eluting beads versus drug-eluting beads alone for transarterial chemoembolization of hepatocellular carcinoma: a multicenter study.
Ji K; Shi Y; Liang Z; Zhang C; Jing L; Xu T; Cao S; Zhou G; Cao Y; Niu J; Zhu J; Ai J; Li Z; Chen F
Acad Radiol; 2024 Jun; ():. PubMed ID: 38866689
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]